Condition: Sarcoma, Synovial · Sarcoma,Soft Tissue · Melanoma Stage IV · Sponsor: Hadassah Medical Organization
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
This description comes directly from the study's public registry record.
Michal Lotem, Prof. · +972058573528 · mlotem@hadassah.org.il
Yafit Halutsi · +972526906339 · yafitha@hadassah.com
Always discuss trial participation with your own doctor first.
| Hadassah Medical Organization | Jerusalem, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05296564